Nodenza Venture Partners Appoints Paul J. Sekhri to Advisory Board

New York, February 19, 2026 – Nodenza Venture Partners (“Nodenza”), a healthcare-focused investment firm specializing in clinical proof-of-concept and product launch life sciences companies, today announced the appointment of Paul J. Sekhri to its Advisory Board.

Mr. Sekhri brings more than three decades of global leadership across biotech innovation, venture capital investing, strategic transactions, and company building. He currently serves as Chairman, President, and Chief Executive Officer of vTv Therapeutics and has previously held senior executive and board roles across the biotechnology, pharmaceutical, and venture capital sectors.

Throughout his career, Mr. Sekhri has led strategic growth initiatives, global business development, and commercialization efforts at major international pharmaceutical organizations, including Sanofi, Teva, and Novartis. He has also served as Chief Executive Officer of multiple venture-backed biotechnology companies and held senior leadership roles at ARIAD Pharmaceuticals and TPG Biotech. His experience spans capital formation, M&A execution, late-stage clinical development, and commercial launch.

“Paul’s perspective bridges early scientific innovation with deep venture investing acumen,” said Ross Morton, Managing Partner of Nodenza Venture Partners. “His experience leading both public and private biotechnology companies, as well as overseeing strategic development within large pharmaceutical platforms, strengthens our ability to support portfolio companies through key value-inflection milestones.”

Mr. Sekhri added, “Nodenza’s strategy of investing across clinical proof-of-concept and product launch stages addresses a critical gap in the life sciences capital landscape. I look forward to contributing to the firm’s continued growth and to supporting the advancement of innovative therapies with meaningful patient impact.”

Nodenza’s investment strategy combines clinical proof-of-concept (IND through Phase 2) with select product launch assets transitioning toward commercialization. The firm partners with founders and management teams to provide both capital and operational guidance as companies progress from scientific validation to market readiness.

Mr. Sekhri’s appointment reflects Nodenza’s continued expansion of its senior advisory network as the firm scales its institutional platform and deepens its engagement with global investors and strategic partners.